12 Month Price Forecast For BHC
Distance to BHC Price Forecasts
BHC Price Momentum
๐ค Considering Bausch Health (BHC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 11:47 AM UTC
BHC Analyst Ratings & Price Targets
Based on our analysis of 14 Wall Street analysts, BHC has a consensus that is neutral. The median price target is $9.50, with forecasts ranging from $7.00 to $12.00. Currently, there are 1 Buy ratings, 4 Hold ratings, and 1 Sell ratings.
With BHC currently trading at $7.34, the median price forecast suggests a 29.4% upside. The most optimistic forecast comes from Douglas Miehm at RBC Capital, projecting a 63.5% upside, while Gregory Fraser at Truist Securities provides the most conservative target, suggesting a -4.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BHC Analyst Consensus
BHC Price Target Range
Latest BHC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BHC.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 30, 2025 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $10.00 |
Nov 1, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $11.00 |
Aug 2, 2024 | Piper Sandler | David Amsellem | Underweight | Downgrade | $3.00 |
Aug 2, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $8.50 |
Jul 25, 2024 | Truist Securities | Gregory Fraser | Hold | Maintains | $7.00 |
Jul 10, 2024 | Raymond James | Michael Freeman | Market Perform | Initiates | $8.00 |
Apr 23, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $11.00 |
Apr 12, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Reiterates | $12.00 |
Apr 5, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $12.00 |
Feb 23, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $9.00 |
Sep 20, 2023 | Jefferies | David Steinberg | Buy | Upgrade | $16.00 |
Jun 16, 2023 | TD Cowen | Ken Cacciatore | Market Perform | Downgrade | $0.00 |
May 22, 2023 | Jefferies | David Steinberg | Buy | Maintains | $9.50 |
May 5, 2023 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $8.00 |
Sep 9, 2022 | Piper Sandler | David Amsellem | Neutral | Maintains | $6.00 |
Sep 1, 2022 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $8.00 |
Aug 10, 2022 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $4.50 |
Aug 10, 2022 | BMO Capital | Gary Nachman | Market Perform | Maintains | $8.00 |
Jul 29, 2022 | Truist Securities | Hold | Downgrade | $0.00 | |
Jul 29, 2022 | JP Morgan | Neutral | Downgrade | $0.00 |
Stocks Similar to Bausch Health Cos Inc
The following stocks are similar to Bausch Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Bausch Health Cos Inc (BHC) Financial Data
Bausch Health Cos Inc has a market capitalization of $2.70B with a P/E ratio of -4.5x. The company generates $9.47B in trailing twelve-month revenue with a -1.9% profit margin.
Revenue growth is +12.2% quarter-over-quarter, while maintaining an operating margin of +21.7% and return on equity of +722.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Bausch Health Cos Inc (BHC) Company Overview
About Bausch Health Cos Inc
Diversified specialty pharmaceutical and medical device company.
The company generates revenue through the development, manufacturing, and marketing of a wide range of pharmaceutical and medical device products across various therapeutic areas, including gastroenterology, dermatology, and ophthalmology. Its operations are segmented into five key areas, allowing it to cater to diverse markets both domestically and internationally.
With a strong focus on innovation and a broad portfolio of products, the company is positioned to meet the growing healthcare needs. Bausch Health Companies Inc. has a history of strategic rebranding and currently operates under its new name since July 2018, reflecting its commitment to evolving its business.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
20,270
CEO
Mr. Thomas J. Appio
Country
Canada
IPO Year
2018
Website
www.bauschhealth.comBausch Health Cos Inc (BHC) Latest News & Analysis
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
14 days agoBausch Health Companies Inc. will release Q4 and full year 2024 financial results on February 19, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
The upcoming earnings release and conference call could impact Bausch Health's stock price, influencing investor sentiment and trading strategies based on performance insights.
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
15 days agoBausch + Lomb (NYSE/TSX: BLCO) will release its Q4 and full-year 2024 financial results on February 19, 2025, followed by a conference call at 8 a.m. ET. Investor materials will be available online.
Bausch + Lomb's upcoming financial results and business update could influence stock performance and investor sentiment, highlighting insights into company growth and market position.
Bausch Health's XIFAXANยฎ has been selected for CMS's drug price negotiations under the Inflation Reduction Act, with initial price applicability set for 2027.
Bausch Health's XIFAXANยฎ facing CMS negotiation could impact pricing and revenue post-2027, affecting future earnings and investor sentiment in the pharmaceutical sector.
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?
21 days agoAnalysts' price targets for Bausch (BHC) suggest a 25.5% upside, supported by consensus on raised earnings estimates, indicating potential stock growth.
Analysts' price targets suggest a 25.5% upside for Bausch (BHC), indicating potential growth, while consensus on earnings estimates signals strong confidence in future performance.
Bausch and Lomb CEO Brent Saunders discussed portfolio changes and growth prospects for the company in a recent interview on 'Money Movers.'
Brent Saundersโ insights on portfolio changes and growth prospects can signal Bausch and Lomb's future performance, influencing investor confidence and stock valuation.
Bausch and Lomb CEO Brent Saunders highlights the negative effects of excessive screen time on vision, indicating a potential market opportunity for eye care products.
Increased screen time concerns may boost demand for eye care products, positively impacting Bausch and Lomb's sales and growth prospects.
Frequently Asked Questions About BHC Stock
What is Bausch Health Cos Inc's (BHC) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Bausch Health Cos Inc (BHC) has a median price target of $9.50. The highest price target is $12.00 and the lowest is $7.00.
Is BHC stock a good investment in 2025?
According to current analyst ratings, BHC has 1 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $7.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BHC stock?
Wall Street analysts predict BHC stock could reach $9.50 in the next 12 months. This represents a 29.4% increase from the current price of $7.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bausch Health Cos Inc's business model?
The company generates revenue through the development, manufacturing, and marketing of a wide range of pharmaceutical and medical device products across various therapeutic areas, including gastroenterology, dermatology, and ophthalmology. Its operations are segmented into five key areas, allowing it to cater to diverse markets both domestically and internationally.
What is the highest forecasted price for BHC Bausch Health Cos Inc?
The highest price target for BHC is $12.00 from Douglas Miehm at RBC Capital, which represents a 63.5% increase from the current price of $7.34.
What is the lowest forecasted price for BHC Bausch Health Cos Inc?
The lowest price target for BHC is $7.00 from Gregory Fraser at Truist Securities, which represents a -4.6% decrease from the current price of $7.34.
What is the overall BHC consensus from analysts for Bausch Health Cos Inc?
The overall analyst consensus for BHC is neutral. Out of 14 Wall Street analysts, 1 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $9.50.
How accurate are BHC stock price projections?
Stock price projections, including those for Bausch Health Cos Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.